Mannitol
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Mannitol: From Osmotic Diuretic Use to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Mannitol is an osmotic diuretic agent; the specific original indication is not documented in this evidence pack, and detailed mechanism-of-action data is currently a data gap. The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this direction is currently supported by only 0 clinical trials and 1 review-level publication, none of which directly test mannitol in this condition.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (Mannitol is generally classified as an osmotic diuretic) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L4 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for mannitol. Based on general pharmacological knowledge, mannitol is an osmotic diuretic that increases free-water excretion by raising plasma osmolality and reducing renal tubular water reabsorption.
NSIAD is a condition in which a gain-of-function mutation in the vasopressin V2 receptor produces an antidiuretic-like state (dilutional hyponatremia) despite low or undetectable ADH levels. The theoretical rationale linking mannitol to NSIAD is that its osmotic diuretic action could, in principle, increase free-water clearance and help correct the hyponatremia seen in NSIAD.
However, this is a mechanistic extrapolation rather than a treatment pathway validated by direct clinical or experimental data. The one supporting publication is a general review on pitfalls in evaluating hyponatremia, which discusses NSIAD as a differential diagnosis but does not evaluate mannitol as a treatment. No clinical trials currently test this drug-disease pairing.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26706473 | 2016 | Review | European Journal of Internal Medicine | Discusses ten common pitfalls in evaluating hyponatremia, including differentiating NSIAD from SIADH; does not evaluate mannitol as a treatment |
EU Market Information
No EU marketing authorization is currently recorded for mannitol in this evidence pack (market status: Not Marketed, 0 authorizations).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted link between mannitol and NSIAD rests on a plausible but unvalidated pharmacological extrapolation, with no supporting clinical trials and only one indirectly relevant review article (Evidence Level L4). This is insufficient to advance beyond initial screening.
To proceed, the following is needed:
- TFDA/SmPC-level warnings and contraindications for mannitol — currently a blocking data gap preventing entry into the S1 safety review stage
- Confirmed mechanism of action (MOA) data from DrugBank or equivalent source, to support or refute the mechanistic rationale
- Direct clinical or preclinical evidence evaluating mannitol specifically in NSIAD or related hyponatremia syndromes
- Clarification of mannitol’s original approved indication(s), which are currently absent from the regulatory data available
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.